Inspections

Surprise inspections often reveal gaps that companies fail to identify internally. Common deficiencies include:

• Disorganized or incomplete documentation
• Employees unaware of inspection protocols
• Batch records with missing or inconsistent entries
• Inadequate training records for operators and quality personnel
• Uncontrolled electronic records and disabled audit trails
• Weak deviation and CAPA follow-up systems
• Failure to provide requested information in a timely manner

These shortcomings not only create negative impressions but also raise questions about overall compliance culture.

Root Causes and Contributing Factors

Root causes of inspection failures typically include:

• Lack of a documented SOP for handling inspections
• Reactive compliance culture instead of continuous readiness
• Poor documentation practices and uncontrolled records
• Inadequate staff training on inspection etiquette and responsibilities
• Failure of management oversight in ensuring audit preparedness

These systemic issues contribute to repeated findings across different facilities and inspections.

How to Prevent and Mitigate GMP Failures

Prevention begins with proactive planning. Companies can mitigate risks by implementing the following best practices:

• Establishing a dedicated inspection management SOP
• Conducting regular mock FDA audits to simulate real inspections
• Ensuring all documents are readily retrievable and controlled
• Training employees on inspection do’s and don’ts, including how to answer investigator questions
• Maintaining an inspection room equipped with controlled access to documents
• Assigning roles such as “front room” for investigator interaction and “back room” for document retrieval

Such proactive measures ensure inspection readiness and minimize the likelihood of negative observations.

Step-by-Step SOP for Surprise FDA Inspections

The following SOP framework can guide companies in handling unannounced FDA inspections:

1. Notification: Security or reception immediately informs the quality head and management when inspectors arrive.
2. Document Verification: Inspect identification credentials of FDA investigators before granting access.
3. Opening Meeting: Quality leadership welcomes the inspectors, outlines company procedures, and ensures communication protocols are established.
4. Escort Assignment: Each inspector is accompanied by a trained company representative.
5. Document Management: All requested documents are retrieved from the back room, verified, and logged before submission.
6. Employee Interaction: Staff should answer questions truthfully, concisely, and only within their area of responsibility.
7. Daily Debrief: Inspectors’ daily comments are captured, discussed internally, and addressed promptly if possible.
8. Closing Meeting: Company management records and acknowledges observations presented by the inspectors.
9. Post-Inspection Response: If a Form 483 is issued, prepare a detailed, timely, and evidence-backed response.

This structured approach ensures inspections are handled with professionalism and confidence.

Corrective and Preventive Actions (CAPA)

If deficiencies are observed during an inspection, the CAPA process must be initiated immediately:

1. Record all observations in the deviation management system
2. Conduct root cause analysis using tools like 5-Why or Fishbone diagram
3. Develop corrective actions to resolve immediate gaps
4. Implement preventive measures to avoid recurrence
5. Assign accountability and timelines for completion
6. Conduct follow-up audits to verify effectiveness
7. Report CAPA closure to management and maintain documentation for future inspections

Regulators assess not only whether CAPA is implemented but also whether it effectively addresses the root cause.

Checklist for Internal Compliance Readiness

• Current and accurate SOPs accessible to employees
• Batch and laboratory records contemporaneous and complete
• Audit trails enabled and periodically reviewed
• All equipment qualified and calibration records up to date
• Deviation and CAPA systems functional and reviewed
• Training logs maintained and competency demonstrated
• Inspection management SOP documented and tested
• Mock audits conducted regularly with findings closed
• Dedicated inspection room equipped and staff trained
• Management actively involved in inspection preparedness

This checklist helps organizations maintain continuous readiness for both scheduled and surprise FDA inspections.

Conclusion: Sustaining Compliance Through Proactive Systems

Surprise FDA inspections are a true test of a company’s GMP compliance culture. Organizations that rely on last-minute preparations often fail, while those with structured SOPs and continuous readiness excel. A comprehensive SOP covering roles, responsibilities, document handling, and employee training ensures transparency, professionalism, and compliance. By embedding inspection readiness into everyday operations, companies can minimize regulatory risks and maintain trust with both regulators and patients.

Abbreviations

• GMP – Good Manufacturing Practice
• FDA – Food and Drug Administration
• SOP – Standard Operating Procedure
• CAPA – Corrective and Preventive Action
• OOS – Out of Specification
• QMS – Quality Management System

References

• FDA 21 CFR Part 211
• FDA Inspection Guides
• EMA Guidelines
• WHO GMP Guidelines